Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma (Fol-BRITe)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01234766
Recruitment Status : Active, not recruiting
First Posted : November 4, 2010
Results First Posted : May 14, 2018
Last Update Posted : September 18, 2018
Spectrum Pharmaceuticals, Inc
Information provided by (Responsible Party):
Frederick Lansigan, Dartmouth-Hitchcock Medical Center

Brief Summary:

The purpose of the study is to learn about the safety and effectiveness of treating follicular lymphoma with bendamustine and rituximab followed by radioimmunotherapy (RIT) using 90-yttrium (Y) ibritumomab tiuxetan.

The researchers will also test blood and bone marrow for the BCL2 gene-Jh that is a commonly found in people with follicular lymphoma (FL) and look at how the BCL2 gene-Jh responds to the study treatment.

Bendamustine is approved by the United States Food and Drug Administration (FDA) for the treatment of chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing treatment regimen. Bendamustine is not approved by the FDA to treat follicular lymphoma.

Rituximab is approved by the FDA for the treatment of relapsed or refractory, low-grade or follicular, CD20-positive B-cell non-Hodgkin's lymphoma.

90-yttrium (Y) ibritumomab tiuxetan is approved by the FDA for the treatment of relapsed or refractory, low-grade or follicular B-cell NHL, including rituximab refractory follicular NHL. It is also approved for the treatment of follicular NHL that is previously untreated with radioimmunotherapy and that achieved a partial or complete response to first-line chemotherapy.

Study participants will will receive bendamustine and rituximab for up to 16 weeks. If participants' cancer responds well to the treatment with bendamustine and rituximab, they will receive up to 12 weeks of radioimmunotherapy (RIT). After the RIT is complete, participants will be asked to return to the clinic every 3 months for a maximum of 10 years for follow-up visits.

Condition or disease Intervention/treatment Phase
Lymphoma, Follicular Drug: Bendamustine Drug: Rituximab Radiation: Y-90 ibritumomab Phase 2

  Show Detailed Description

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 39 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicenter, Open Label, Phase II Study of Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma (Fol-BRITe Study)
Study Start Date : October 2010
Actual Primary Completion Date : June 2014
Estimated Study Completion Date : December 2020

Arm Intervention/treatment
Experimental: Single Arm
Subjects will receive bendamustine and rituximab, followed by 90-yttrium (Y) Ibritumomab Tiuxetan
Drug: Bendamustine
90mg/m2, IV - Days 1 and 2 of every cycle

Drug: Rituximab
375mg/m2, IV - Cycle 1 only: Day -7 (+1 day) Day 1 of every cycle
Other Name: Rituxan

Radiation: Y-90 ibritumomab
0.4mCi/kg, IV - Within 4 hours of rituximab, give over 10 minutes

Primary Outcome Measures :
  1. Number of Participants With Complete Response at 3 Years [ Time Frame: 3 years ]
    The primary endpoint is complete response (CR) rate. Historical complete response (CR) rate has been 35%. This rate will be considered as the null hypothesis.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Previously untreated, histologically confirmed follicular lymphoma classification grade 1, 2 or 3a
  • Ann Arbor stages of II to IV with either symptomatic or bulky disease (>5 cm); or disease progression
  • 18 years of age or older
  • ECOG PS <2
  • Normal organ and marrow function defined as below:

Absolute neutrophil count (ANC) >= 1,000/mm3 Platelet count >=100,000/mm3 Patients with ANC less than 1,000/mm3 and/or platelets below 100,000/mm3 are still eligible for study entry as long as there is >50% bone marrow involvement with lymphoma

  • Adequate hepatic function
  • Adequate renal function
  • Measureable disease with at least one lesion measuring > 2cm in its greatest transverse diameter
  • Female subjects of childbearing potential must have a negative pregnancy test (urine or serum b-HCG) at screening and within 1 week prior to the start of treatment with Y-90 ibritumomab tiuxetan
  • Voluntary written informed consent must be given before performance of any study-related procedure

Exclusion Criteria:

  • Prior chemotherapy, immunotherapy, or monoclonal antibody therapy
  • Receiving any other investigational agents
  • Primary CNS lymphoma
  • Known HIV
  • Treatment with therapeutic doses of systemic steroids within 4 weeks of beginning study treatment (cycle 1, day -7); topical use of corticosteroids and systemic replacement of corticosteroids for adrenal insufficiency are allowed
  • Malignant pleural, pericardial or peritoneal effusions
  • Known history of myelodysplastic syndrome (MDS) or found to have MDS
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would, in the judgment of the investigator, limit compliance with study requirements
  • Pregnant or lactating female subjects
  • Concurrent active malignancy other than lymphoma or history of invasive malignancy within the past 5 years, except completely excised, non-melanoma skin cancer
  • Known Hepatitis B and/or Hepatitis C Infection
  • Any other condition, that in the judgment of the investigator places the patient at unacceptable risk if he/she were to participant in the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01234766

United States, Maine
Maine Center for Cancer Medicine
Scarborough, Maine, United States, 04074
United States, New Hampshire
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, United States, 03756
United States, North Carolina
Duke University Medical Center
Durham, North Carolina, United States, 27710
United States, Rhode Island
Rhode Island Hospital
Providence, Rhode Island, United States, 02903
Sponsors and Collaborators
Dartmouth-Hitchcock Medical Center
Spectrum Pharmaceuticals, Inc
Principal Investigator: Frederick Lansigan, MD Dartmouth-Hitchcock Medical Center

Responsible Party: Frederick Lansigan, Assistant Professor of Medicine, Dartmouth-Hitchcock Medical Center Identifier: NCT01234766     History of Changes
Other Study ID Numbers: D1015
First Posted: November 4, 2010    Key Record Dates
Results First Posted: May 14, 2018
Last Update Posted: September 18, 2018
Last Verified: August 2018

Additional relevant MeSH terms:
Lymphoma, Follicular
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin
Bendamustine Hydrochloride
Antibodies, Monoclonal
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action